The U.S. generics industry is facing significant competitive and pricing pressure, thereby hurting sales in Teva's Generic segment. An increase in FDA generic drug approvals and ongoing customer consolidation are resulting in additional competitive pressure in the industry. The ongoing consolidation of customers in the generics industry led to increasing price erosion. The consolidation in the industry has increased the ability to negotiate lower prices for generic drugs. Accelerated FDA approval of additional generic versions of competing off-patent medicines, increased competition for its largest product - Concerta authorized generic, lower-than-expected contribution of generic launches and stringent government regulations are also hurting sales of the Generics segment.